Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 137

1.

Renin-angiotensin system antagonists in the perioperative setting: clinical consequences and recommendations for practice.

Auron M, Harte B, Kumar A, Michota F.

Postgrad Med J. 2011 Jul;87(1029):472-81. doi: 10.1136/pgmj.2010.112987. Epub 2011 Mar 25. Review.

PMID:
21441164
2.

Optimal antagonism of the Renin-Angiotensin-aldosterone system: do we need dual or triple therapy?

Werner C, Pöss J, Böhm M.

Drugs. 2010 Jul 9;70(10):1215-30. doi: 10.2165/11537910-000000000-00000. Review.

PMID:
20568830
3.

Inhibition of the renin angiotensin aldosterone system: focus on aliskiren.

Rao MS.

J Assoc Physicians India. 2010 Feb;58:102-8. Review.

PMID:
20653151
4.

[Direct renin inhibitor aliskiren in the treatment of cardiovascular and renal diseases].

Horký K.

Vnitr Lek. 2010 Feb;56(2):120-6. Review. Czech.

PMID:
20329582
5.
6.

Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors.

Weir MR, Rolfe M.

Clin J Am Soc Nephrol. 2010 Mar;5(3):531-48. doi: 10.2215/CJN.07821109. Epub 2010 Feb 11. Review.

7.

Aliskiren in the treatment of hypertension and organ damage.

Riccioni G.

Cardiovasc Ther. 2011 Feb;29(1):77-87. doi: 10.1111/j.1755-5922.2010.00230.x. Epub 2010 Nov 25. Review.

PMID:
21106033
8.

Renal and cardio-protective effects of direct renin inhibition: a systematic literature review.

Lambers Heerspink HJ, Perkovic V, de Zeeuw D.

J Hypertens. 2009 Dec;27(12):2321-31. doi: 10.1097/HJH.0b013e3283310f92. Review.

PMID:
19727007
9.

Role of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and aldosterone antagonists in the prevention of atrial and ventricular arrhythmias.

Makkar KM, Sanoski CA, Spinler SA.

Pharmacotherapy. 2009 Jan;29(1):31-48. doi: 10.1592/phco.29.1.31. Review.

PMID:
19113795
10.

Blockade of the renin-angiotensin system in African Americans with hypertension and cardiovascular disease.

Saunders E, Gavin JR 3rd.

J Clin Hypertens (Greenwich). 2003 Jan-Feb;5(1 Suppl 1):12-7.

11.

Modulation of the renin-angiotensin-aldosterone system in sepsis: a new therapeutic approach?

Salgado DR, Rocco JR, Silva E, Vincent JL.

Expert Opin Ther Targets. 2010 Jan;14(1):11-20. doi: 10.1517/14728220903460332. Review.

PMID:
20001206
12.

[The future of renin inhibition].

Uresin AY, Baran E.

Turk Kardiyol Dern Ars. 2009 Oct;37 Suppl 7:32-8. Turkish.

13.

[Oral inhibitors of renin and their potential use as therapeutic agents in treating hypertension].

Abassi Z, Armaly Z, Nakhoul F, Hoffman A.

Harefuah. 2008 Jun;147(6):536-42, 573. Review. Hebrew.

PMID:
18693632
14.

Aliskiren: a new inhibitor of renin-angiotensin aldosterone system activity.

Dalla Vestra M, Simioni N, Masiero A.

Minerva Endocrinol. 2009 Dec;34(4):333-8. Review.

PMID:
20046162
15.

Angiotensin II reactivation and aldosterone escape phenomena in renin-angiotensin-aldosterone system blockade: is oral renin inhibition the solution?

Athyros VG, Mikhailidis DP, Kakafika AI, Tziomalos K, Karagiannis A.

Expert Opin Pharmacother. 2007 Apr;8(5):529-35. Review.

PMID:
17376010
16.

Direct inhibition of renin: a physiological approach to treat hypertension and cardiovascular disease.

Ram CV.

Future Cardiol. 2009 Sep;5(5):453-65. doi: 10.2217/fca.09.31. Review.

PMID:
19715410
17.
18.

Renin inhibitors in chronic heart failure: the Aliskiren Observation of Heart Failure Treatment study in context.

Krum H, Maggioni A.

Clin Cardiol. 2010 Sep;33(9):536-41. doi: 10.1002/clc.20828. Review.

19.

The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease.

Remuzzi G, Perico N, Macia M, Ruggenenti P.

Kidney Int Suppl. 2005 Dec;(99):S57-65. Review.

PMID:
16336578
20.

[Renin-angiotensin-aldosterone system (RAAS) and its pharmacologic modulation].

Giestas A, Palma I, Ramos MH.

Acta Med Port. 2010 Jul-Aug;23(4):677-88. Epub 2010 Jul 30. Review. Portuguese.

Items per page

Supplemental Content

Write to the Help Desk